The 2021 EUFEMED Conference provides us with an opportunity to hear from stakeholders about the challenges they faced, and how they addressed them. Further, we will discuss their experience during the pandemic and its potential impact on the way we work in the field of exploratory medicines development in the future.
The EUFEMED board
EUFEMED is a federation of European organizations and associations active in early clinical medicines development since 2007. A successful collaboration of national bodies, EUFEMED strives to be a voice in the interest of exploratory medicines development.
EUFEMED promotes the interest of early clinical medicines development in professional organizations, international organizations and regulatory authorities. Our aims are to support stakeholders and facilitate networking through conferences, courses and specialist training. We also collaborate with other organizations to develop standards and promote guidance in early medicines development in order to improve European competitiveness.
Our conference are well attended from across the industry and we invite you to take the opportunity to meet our members in a learning environment.
Kerstin Breithaupt-Grögler² (AGAH), Henri Caplain¹ (AFPT), Yves Donazzolo¹’² (AFPT), Tim Hardman¹ (AHPPI),
Jan de Hoon¹ (Healixia), Ingrid Klingmann¹’² (AGAH), Andreas Kovar¹ (AGAH), Erik Mannaert¹ (Healixia),
Jens Rengelshausen¹ (AGAH), Hildegard Sourgens² (AGAH), Bettina Ziegele¹ (AGAH)
Attend the virtual conference >>
Plan your schedule with the programme >>
Get more information with at the program >>